FDA Approves First Needle-Free Treatment for Severe Allergic Reactions

New Nasal Spray Provides Rapid Relief

Washington, D.C. - August 9, 2024

The Food and Drug Administration (FDA) has approved the first needle-free epinephrine nasal spray for the treatment of severe allergic reactions. The spray, known as neffy, is designed to be a more convenient and less intimidating option for individuals at risk of anaphylaxis, a potentially life-threatening allergic reaction.

"This approval is a major step forward in the treatment of anaphylaxis," said FDA Commissioner Dr. Robert M. Califf. "Neffy provides a safe and effective alternative to epinephrine auto-injectors, which can be difficult or frightening to use in emergency situations."

Neffy is administered as a single spray into each nostril. It rapidly absorbs into the bloodstream, delivering epinephrine to the body to constrict blood vessels and open airways. Epinephrine is a hormone that is naturally produced by the body in response to stress or danger. It can quickly reverse the life-threatening symptoms of anaphylaxis, such as difficulty breathing, swelling of the throat or face, and a rapid drop in blood pressure.